Latest News - MIGS

Thursday, April 13, 2017 | Acquisitions/Mergers, Glaucoma, Glaukos Corporation, MIGS

Glaukos Corporation Acquires IOP Sensor System from DOSE Medical

Glaukos announced that it has acquired the IOP sensor system assets and related liabilities from DOSE Medical Corporation for $5.5 million in cash, plus performance-based consideration of up to $9.5 m…

Read the full story

Thursday, April 13, 2017 | Glaucoma, MIGS

Sight Sciences Announces Health Canada Approval of the VISCO360 Viscosurgical System for Standalone Microinvasive Glaucoma Surgery (MIGS)

Sight Sciences announced that it has received Health Canada approval for the VISCO360 Viscosurgical System. The VISCO360 System is indicated in Canada for the microcatheterization and transluminal vis…

Read the full story

Thursday, March 23, 2017 | Conferences, Ellex, MIGS

Ellex to Broadcast ABiC Surgery Event Live From Dean McGee Eye Institute

Ellex Medical will host a live online broadcast of its minimally invasive glaucoma surgery (MIGS) procedure ABiC (ab interno canaloplasty) on Tuesday, March 28, 2017 at the Dean McGee Eye Institute, U…

Read the full story

Thursday, March 16, 2017 | Glaucoma, Glaukos Corporation, MIGS

Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Microinvasive Glaucoma Surgery

Glaukos announced that the Current Procedural Terminology (CPT) Editorial Panel of the American Medical Association has granted 5-year extensions to three Category III CPT codes that describe insertio…

Read the full story

Thursday, February 16, 2017 | Clinical Trials, Glaukos Corporation, MIGS

Glaukos Completes Patient Enrollment in Pivital Phase of US IDE Clinical Trial for iStent Supra

Glaukos announced the completion of patient enrollment in the pivotal phase of its FDA investigational device exemption (IDE) trial for the iStent Supra Suprachoroidal Micro-Bypass Stent. The iSten…

Read the full story

Tuesday, February 14, 2017 | Glaucoma, Allergan, MIGS

Allergan Announces First Commercial Use of XEN Glaucoma Treatment System in the US

Allergan announced that its XEN Glaucoma Treatment System is now being used by US surgeons to treat refractory glaucoma. The XEN Glaucoma Treatment System, consisting of the XEN45 Gel Stent and the XE…

Read the full story

Monday, December 19, 2016 | Medical Studies, MIGS, Prevent Blindness

Number of Glaucoma Cases Projected to Increase Significantly Due To Aging US Population, Prevent Blindness Offers Free Educational Resources

Glaucoma currently affects nearly 3 million people ages 40 and older, according to the Prevent Blindness report, “Future of Vision: Forecasting the Prevalence and Costs of Vision Problems.&rdquo…

Read the full story

Tuesday, November 22, 2016 | FDA Approval/Clearance, Product Releases, Allergan, MIGS

Allergan Receives FDA Clearance for the XEN Gel Stent, a New Surgical Treatment for Refractory Glaucoma

Allergan announced that the FDA has cleared the XEN Glaucoma Treatment System, which consists of the XEN45 Gel Stent and the XEN Injector. The XEN Glaucoma Treatment System reduces IOP in patients and…

Read the full story

Tuesday, November 08, 2016 | Clinical Trials, Glaucoma, Medical Studies, Glaukos Corporation, MIGS

New International Study Highlights IOP-Lowering Performance of Glaukos iStent inject Trabecular Micro-Bypass in Standalone Procedure

Glaukos announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open angle glaucoma achieved a ≥ 20% reduction in unmedicated IOP 1 year after implantation of the iS…

Read the full story

Monday, October 31, 2016 | Clinical Trials, Glaucoma, Glaukos Corporation, MIGS

Report: iStent Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population

Glaukos Corporation announced that a study of 134 predominantly Hispanic eyes with open-angle glaucoma (OAG), published in Clinical Ophthalmology, showed mean IOP of 12.9 mm Hg and a 61% decrease in m…

Read the full story

Monday, October 17, 2016 | Product Releases, Alcon, MIGS

Alcon Launches the CyPass Micro-Stent

Alcon announced the US launch of the CyPass Micro-Stent at the annual meeting of the American Academy of Ophthalmology in Chicago. The CyPass Micro-Stent was approved by the FDA in July for use in con…

Read the full story

Tuesday, September 27, 2016 | Glaucoma, Medical Studies, Glaukos Corporation, MIGS

New Study Underscores Ability of iStent to Achieve Sustained Reductions in IOP and Medication Use

A study published in Clinical Ophthalmology showed that a consistent cohort of 107 open-angle glaucoma (OAG) eyes receiving the iStent Trabecular Micro-Bypass Stent in combination with cataract surger…

Read the full story

Friday, September 23, 2016 | Glaucoma, Medical Studies, Glaukos Corporation, MIGS

International Study Shows Favorable 3-Year Results of 2 Glaukos iStent Trabecular Micro-Bypass Stents as Initial Treatment for Naïve Glaucoma

Glaukos announced that an international study published in Ophthalmology and Therapy showed that newly diagnosed primary open-angle glaucoma patients achieved a 43% reduction in mean IOP to 14.6 mm Hg…

Read the full story